Mint. "In view of the above, you are hereby directed to convey the matter to all the manufacturer under your jurisdiction and cancel the product permission granted by you of subject drug," it added.
In India, the combination of meropenem and disodium EDTA is marketed as a broad-spectrum antibacterial agent for the treatment of a variety of infections, including meningitis, pneumonia, urinary tract infections, intra-abdominal infections, gynaecological infections, skin infections, and sepsis. Produced by numerous local pharmaceutical companies, the drug is offered at a price of around ₹2,000 per dose.
Read more on livemint.com